Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years

Andreas Karabis,1 Michelle Mocarski,2 Indra Eijgelshoven,1 Gert Bergman1 1Mapi HEOR and Strategic Market Access, Houten, the Netherlands; 2Forest Research Institute, Jersey City, NJ, USA Purpose: Aclidinium bromide is a long-acting muscarinic antagonistic used in maintenance treatment of chronic ob...

Full description

Bibliographic Details
Main Authors:	Karabis A, Mocarski M, Eijgelshoven I, Bergman G
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-04-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/economic-evaluation-of-aclidinium-bromide-in-the-management-of-moderat-a16346

Similar Items

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis
by: Karabis A, et al.
Published: (2013-09-01)

An update on the efficacy and safety of aclidinium bromide in patients with COPD
by: Khuder Alagha, et al.
Published: (2011-02-01)

Cost versus utility of aclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg alone in the management of moderate-to-severe COPD
by: Ramos M, et al.
Published: (2016-09-01)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
by: Moitra S, et al.
Published: (2015-04-01)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
by: Anthony D. D’Urzo, et al.
Published: (2019-05-01)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
by: Contoli M, et al.
Published: (2016-12-01)

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
by: Sims MW, et al.
Published: (2011-09-01)

The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease
by: François Maltais, et al.
Published: (2012-12-01)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
by: Jones PW
Published: (2015-03-01)

Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease
by: K. Suresh Babu, et al.
Published: (2015-04-01)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
by: Watz H, et al.
Published: (2017-08-01)

Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study
by: Jutta Beier, et al.
Published: (2013-08-01)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
by: Miravitlles M, et al.
Published: (2016-08-01)

Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
by: Monteagudo M, et al.
Published: (2017-04-01)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
by: Li W, et al.
Published: (2023-11-01)

The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
by: Wise RA, et al.
Published: (2021-03-01)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
by: D&rsquo;Urzo A
Published: (2013-08-01)

A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study
by: Kostikas K, et al.
Published: (2020-03-01)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
by: Matera MG, et al.
Published: (2016-01-01)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
by: Dave Singh, et al.
Published: (2017-05-01)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)

Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD
by: Laura Miranda de Oliveira Caram, et al.

Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
by: Wilson MR, et al.
Published: (2017-03-01)

Efficacy of azoximer bromide in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia
by: S. K. Zyryanov, et al.
Published: (2021-12-01)

Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis
by: Rachel E Jordan, et al.
Published: (2015-05-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
by: D'Urzo AD, et al.
Published: (2019-02-01)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
by: Buhl R, et al.
Published: (2012-10-01)

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis
by: Huisman EL, et al.
Published: (2015-09-01)

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
by: Ismaila AS, et al.
Published: (2015-11-01)

Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting
by: Peter Lange, et al.
Published: (2016-07-01)

Glycopyrronium bromide is a new long-acting anticholinergic drug for the treatment of COPD
by: S. N. Avdeev, et al.
Published: (2014-12-01)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
by: Horita N, et al.
Published: (2015-04-01)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
by: James F. Donohue, et al.
Published: (2019-10-01)

Determinants of change in physical activity during moderate-to-severe COPD exacerbation
by: Esteban C, et al.
Published: (2016-02-01)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
by: Buhl R, et al.
Published: (2014-03-01)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
by: Calverley PM, et al.
Published: (2016-12-01)